RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsMay 03, 2024 - South Korean CDMO company Samsung Biologics is set to thrive if the BIOSECURE ACT is passed, as would late-stage biologic clinical development companies like ONCY.
"China-based organizations have come under scrutiny following the introduction of the BIOSECURE bill, and the federal government will be continuously monitoring joint ventures between US-based companies and their Chinese partners, which makes it necessary to find new, reliable, and capable partners. Many CDMO businesses worldwide, like Swedish-headquartered Recipharm AB., or Japanese firms AGC Inc., and Fujifilm Corp., would try to latch on to this opportunity."
https://www.globaldata.com/media/pharma/samsung-biologics-set-thrive-biosecure-bill-passes-us-says-globaldata/